Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Lyka Labs
|
Zenotech Laboratorie
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-52.11 % | 62.44 % | 9.5 % |
|
5yr average Equity Multiplier
|
3.77 | 2.9 | 1.13 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.73 | 0.36 |
|
5yr Avg Net Profit Margin
|
-36.55 % | -0.79 % | -13.89 % |
|
Price to Book
|
3.11 | 2.52 | 2.84 |
|
P/E
|
30.08 | 0.0 | 82.63 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | 32.55 Days | -1217.81 Days |
|
Inventory Days
|
87.65 Days | 24.2 Days | 145.01 Days |
|
Days Receivable
|
132.64 Days | 92.33 Days | 61.38 Days |
|
Days Payable
|
210.48 Days | 106.74 Days | 477.06 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | 2.2 | -4.03 |
|
5yr Avg ROCE
|
-11.61 % | 25.83 % | 9.71 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | 24.02 % | 5.56 % |
|
5 yr average Debt to Equity
|
1.41 | 1.25 | 0.04 |
|
5yr CAGR Net Profit
|
12.0 % | n/a | n/a |
|
5yr Average Return on Assets
|
-16.11 % | 1.72 % | 8.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 58.16 % | 68.84 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.02 % | 10.57 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | -3.53 % | 0.0 |
|
Bafna Pharma
|
Lyka Labs
|
Zenotech Laboratorie
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|